Aquinox Pharmaceuticals Inc

Most Recent

  • uploads///Cara SGA
    Company & Industry Overviews

    Comparing Cara Therapeutics’ Financial Performance

    Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]

    By Kenneth Smith
  • uploads///oral CR
    Company & Industry Overviews

    Cara Therapeutics’ Collaboration Agreements

    Oral CR845 for treating chronic kidney disease–associated pruritus In July 2017, Cara Therapeutics (CARA) announced the results from a Phase 1 safety and pharmacokinetics study of oral CR845 in patients with chronic kidney disease (or CKD) undergoing hemodialysis. The results showed that the four dosage strengths evaluated in the study were well tolerated. In October […]

    By Kenneth Smith
  • uploads///Cara Analysts reco
    Company & Industry Overviews

    Analysts’ Recommendations for Cara Therapeutics in January 2018

    Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.

    By Kenneth Smith
  • uploads///gks
    Earnings Report

    How Has Aquinox Performed Compared to Peers?

    Aquinox has a positive future outlook and will likely continue to better its performance in the near future.

    By Gabriel Kane
  • uploads///gks
    Earnings Report

    Aquinox Improves Net Income with New Discoveries

    Aquinox Pharmaceuticals (AQXP) has achieved success in the field of discovery and development of new drugs.

    By Gabriel Kane
  • uploads///gks
    Earnings Report

    Aquinox’s Journey from the Bottom to the Top

    As per Aquinox’s 2Q15 earnings report, the company’s net income has gone up by 25.9% as compared to 1Q15 earnings of 20.76%.

    By Gabriel Kane
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.